SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
- None.
- None.
Insights
SELLAS Life Sciences' recent public offering is a strategic move to raise capital, which is critical for the company's operations and future research endeavors. The offering of 12 million shares, coupled with the same number of warrants at $0.75, is set to generate $9 million in gross proceeds. This capital injection should be scrutinized in terms of dilution effect on current shareholders, as it increases the total number of shares outstanding, potentially reducing the value of existing shares.
Moreover, the pricing of the warrants, which are also at $0.75 and immediately exercisable, could indicate the company's urgent need for funds, as this might seem unattractive to investors if the current share price is above the exercise price. However, the five-year expiration on these warrants provides a lengthy window for exercise, which could be seen as a vote of confidence in the company's long-term prospects.
Investors should consider how this capital will be deployed. If used effectively for advancing clinical trials or expanding the product pipeline, it could lead to significant long-term value creation. Conversely, if the funds are not managed efficiently, it could lead to a decline in shareholder value.
The biopharmaceutical sector is heavily reliant on continuous funding due to the high costs associated with research and development. SELLAS Life Sciences' decision to raise funds through a public offering is a common practice within the industry to sustain operations and support clinical trials. The market's response to such a public offering can often be an indicator of investor confidence in the company's growth potential and the perceived risk-reward ratio of the investment.
It is important to analyze the competitive landscape and the demand for novel cancer therapies. If SELLAS is developing treatments with a strong differentiation factor or targeting unmet medical needs, the potential for market penetration and future revenue streams could justify the dilutive effect of the offering. On the other hand, if the market perceives the company's pipeline as weak or the competition as too intense, the offering could be seen as a negative signal.
The biotechnology industry is driven by innovation and the successful development of new therapies. SELLAS Life Sciences is operating in a field with substantial R&D costs, regulatory hurdles and a long timeline to market for its products. The financial health of the company and its ability to continue funding its research pipeline are pivotal for its survival and growth.
Investors should assess the company's current stage in the clinical trial process and the potential of its cancer therapies. If the therapies in development have shown promising results or are nearing the end of the clinical trial phase, the offering could be seen as a necessary step towards bringing a viable product to market. Conversely, if the company is in the early stages of development with no clear path to commercialization, the risk is significantly higher.
Understanding the scientific validity and market need for the company's cancer therapies is essential. The success rate of similar therapies and the company's intellectual property position should also be considered in evaluating the long-term prospects of SELLAS Life Sciences.
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced public offering for the purchase and sale of 12,000,000 shares of common stock (or common stock equivalents in lieu thereof) and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of common stock at a combined purchase price of
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The closing of the offering is expected to occur on or about January 8, 2024, subject to the satisfaction of customary closing conditions.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-255318) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that SELLAS has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about SELLAS and such offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009), a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements about the Company’s expectations regarding the use of net proceeds of the proposed offering and other information that is not historical information. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 16, 2023 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
FAQ
What did SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announce?
What is the exercise price of the warrants?
Who is acting as the sole placement agent for the offering?
When is the closing of the offering expected to occur?
